Ahead of US gene ther­a­py ex­plo­sion, big con­tract drug man­u­fac­tur­er Catal­ent makes $1.2 bil­lion bet on Paragon Bioser­vices

As drug de­vel­op­ers ag­gres­sive­ly pur­sue gene ther­a­pies and their mak­ers, the man­u­fac­tur­ing end of the sup­ply chain is al­so for­ti­fy­ing it­self for the wave of ther­a­pies ex­pect­ed to hit the mar­ket in the com­ing years. Less than a month af­ter Ther­mo Fish­er un­veiled a $1.7 bil­lion deal to swal­low Bram­mer Bio — a com­pa­ny that does con­tract vi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py de­vel­op­ers — Catal­ent is plan­ning to fork over $1.2 bil­lion for pri­vate-eq­ui­ty backed Paragon Bioser­vices.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.